Patents by Inventor James D. Isbister

James D. Isbister has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Once a day amoxicillin product comprising immediate and delayed release dosage forms
    Patent number: 8889187
    Abstract: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: November 18, 2014
    Assignee: Shionogi Inc.
    Inventors: Edward M Rudnic, James D Isbister, Donald J Treacy, Jr., Sandra E Wassink
  • Antifungal once-a-day product, use and formulation thereof
    Patent number: 8303988
    Abstract: An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: November 6, 2012
    Assignee: Shionogi Inc.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • ANTIBIOTIC PRODUCT, USE AND FORMULATION THEREOF
    Publication number: 20120035121
    Abstract: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, JR., Sandra E. Wassink
  • Antifungal Product, Use and Formulation Thereof
    Publication number: 20110065718
    Abstract: An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 17, 2011
    Applicant: Victory Pharma, Inc.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, JR., Sandra E. Wassink
  • Antiviral product, use and formulation thereof
    Patent number: 7282221
    Abstract: An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: October 16, 2007
    Assignee: Middlebrook Pharmaceuticals, Inc.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Multiple-delayed release antifungal product, use and formulation thereof
    Patent number: 7157095
    Abstract: An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-fungal product being reached in less than about twelve hours after initial release of anti-fungal from the product.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: January 2, 2007
    Assignee: Advancis Pharmaceutical Corporation
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Antineoplastic product, use and formulation thereof
    Patent number: 7108859
    Abstract: An antineoplastic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antineoplastic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: October 21, 2002
    Date of Patent: September 19, 2006
    Assignee: Advancis Pharmaceutical Corporation
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Multiple-delayed release anti-neoplastic product, use and formulation thereof
    Patent number: 7105174
    Abstract: An anti-neoplastic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-neoplastic product being reached in less than about twelve hours after initial release of anti-neoplastic from the product.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: September 12, 2006
    Assignee: Advancis Pharmaceutical Corporation
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Multiple-delayed release anti-viral product, use and formulation thereof
    Patent number: 7074417
    Abstract: An anti-viral product is comprised of at least three delayed release dosage forms, each of which has a different release profile, with the Cmax for the anti-viral product being reached in less than about twelve hours after initial release of anti-viral from the product.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: July 11, 2006
    Assignee: Advancis Pharmaceutical Corporation
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Multiple-delayed released antibiotic product, use and formulation thereof
    Patent number: 7025989
    Abstract: An antibiotic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: April 11, 2006
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Antibiotic composition
    Patent number: 6991807
    Abstract: Disclosed are antibiotic products for delivering at least two different antibiotics, wherein the products are comprised of at least three or four dosage forms with different release profiles and the at least two different antibiotics comprise at least one protein synthesis inhibiting antibiotic and at least one non-protein synthesis inhibiting antibiotic.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: January 31, 2006
    Assignee: Advancis Pharmaceutical, Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Antiviral product, use and formulation thereof
    Patent number: 6984401
    Abstract: An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: January 10, 2006
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Anti-fungal composition
    Patent number: 6929804
    Abstract: An anti-fungal product for delivering at least two different anti-fungals that is comprised of three dosage forms with different release profiles with each anti-fungal being present in at least one of the dosage forms.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: August 16, 2005
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Tetracycline antibiotic product, use and formulation thereof
    Patent number: 6730320
    Abstract: An antibiotic product, in particular a tetracycline, such as doxycycline, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: May 4, 2004
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Antibiotic product, use and formulation thereof
    Patent number: 6723341
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: April 20, 2004
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Antibiotic product, use and formulation thereof
    Publication number: 20040052842
    Abstract: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: July 1, 2003
    Publication date: March 18, 2004
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Antibiotic composition
    Publication number: 20040018234
    Abstract: Disclosed are antibiotic products for delivering at least two different antibiotics, wherein the products are comprised of at least three or four dosage forms with different release profiles and the at least two different antibiotics comprise at least one protein synthesis inhibiting antibiotic and at least one non-protein synthesis inhibiting antibiotic.
    Type: Application
    Filed: May 19, 2003
    Publication date: January 29, 2004
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Antibiotic product, use and formulation thereof
    Patent number: 6669948
    Abstract: An antibiotic product, in particular a betalactam such as cephalosporin (in particular cefuroxime and/or cefpodoxime) or a penicillin (in particular axmoxicillin or dicloxacillin) is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: December 30, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Levofloxacin antibiotic product, use and formulation thereof
    Patent number: 6667057
    Abstract: An antibiotic product, in particular levofloxacin, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: December 23, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Fluroquinilone antibiotic product, use and formulation thereof
    Patent number: 6667042
    Abstract: An antibiotic product, in particular a fluroquinilone such as ciprofloxacin, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: December 23, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink